Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tysabri Return Depends On Patient Group Input, CDER Deputy Says

May 16 2005

• By The Pink Sheet

Related Content

Natrecor Labeling Revised To Include Expanded Mortality Analysis

Apr 25 2005

Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial

Mar 07 2005

Positive inotropic agent labeling should discuss risks of long-term use in CHF -- FDA advisory committee.

Feb 02 1998

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window